Amgen Inc. AMGN
414.61
8.57
2.11%
as of 25 Sep
- Market cap
- $219.1B
- P/E
- 25.6×
Follow AMGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Amgen Inc. (AMGN) Debt to equity
Amgen Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 4.9×, down 1.4× from fiscal 2025 (6.3×). Over the past ten years it has ranged from 1.1× (fiscal 2015) to 10.6× (fiscal 2022); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Annual
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 6.3× | (38.33%) |
| FY2024 | 10.2× | (1.37%) |
| FY2023 | 10.4× | (2.54%) |
| FY2022 | 10.6× | 113.98% |
| FY2021 | 5.0× | 41.81% |
| FY2020 | 3.5× | 13.40% |
| FY2019 | 3.1× | 13.89% |
| FY2018 | 2.7× | 93.85% |
| FY2017 | 1.4× | 20.92% |
| FY2016 | 1.2× | 3.48% |
Quarterly
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 4.9× | (21.40%) |
| Mar 2026 | 6.2× | (1.10%) |
| Dec 2025 | 6.3× | 11.13% |
| Sep 2025 | 5.7× | (25.00%) |
| 42 more quarters | Free account |
Against its own ten years
Low 1.1×
High 10.6×
Ten-year median
3.5×
Current reading's percentile
73
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ABBV AbbVie Inc. compare | −12.0× |
| AZN AstraZeneca PLC compare | 0.6× |
| NVO Novo Nordisk A/S compare | 0.6× |
| PFE Pfizer Inc. compare | 0.7× |
| NVS Novartis AG compare | 1.1× |
| MRK Merck & Co., Inc. compare | 1.2× |
| BMY Bristol Myers Squibb Company compare | 1.9× |
| GILD Gilead Sciences, Inc. compare | 2.2× |
| AMGN Amgen Inc. | 4.9× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.2× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on AMGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement